1710-55-0

Basic information

• Product Name: 2,3-dihydro-5-methoxy-1,4-benzodioxin
• Synonyms: 2,3-dihydro-5-methoxy-1,4-benzodioxin;5-Methoxy-2,3-dihydro-1,4-benzodioxin
• CAS NO: 1710-55-0
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.1739
• EINECS: 216-972-6
• Mol File: 1710-55-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 239.6°Cat760mmHg
• Flash Point: 78.2°C
• Appearance: /
• Density: 1.167g/cm³
• Vapor Pressure: 0.0613mmHg at 25°C
• Refractive Index: 1.526
• CAS DataBase Reference: 2,3-dihydro-5-methoxy-1,4-benzodioxin(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-5-methoxy-1,4-benzodioxin(1710-55-0)
• EPA Substance Registry System: 2,3-dihydro-5-methoxy-1,4-benzodioxin(1710-55-0)

Safety Data

• Hazardous Substances Data: 1710-55-0(Hazardous Substances Data)

Usage

General Description

2,3-dihydro-5-methoxy-1,4-benzodioxin, also known as 5-Methoxy-1,4-benzodioxane, is a chemical compound with the molecular formula C9H10O3. It is a white solid with a faint odor, and its structure consists of a dioxin ring with a methoxy substituent at the 5-position. 2,3-dihydro-5-methoxy-1,4-benzodioxin is widely used in the pharmaceutical industry as an intermediate for the synthesis of various drugs, including those used to treat cardiovascular diseases and central nervous system disorders. It is also used in organic synthesis as a building block for the preparation of complex organic molecules. 2,3-dihydro-5-methoxy-1,4-benzodioxin is considered to be relatively stable and has low toxicity, making it a valuable chemical in both research and industrial applications.

InChI:InChI=1/C9H10O3/c1-10-7-3-2-4-8-9(7)12-6-5-11-8/h2-4H,5-6H2,1H3

Upstream product

• 934-00-9 3-methocycatechol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 10288-36-5 2,3-dihydro-1,4-benzodioxin-5-ol 
• 190661-82-6 5-bromo-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxine 
• 260561-48-6 cis-4-cyano-4-(2,3-dihydro-8-methoxy-1,4-benzodioxin-5-yl)cyclohexanecarboxylic acid 

Relevant articles and documents

Urea substituted aromatic ring connected dioxane and quinazoline or quinoline compound, composition and application thereof (by machine translation)

The invention relates to a novel compound VEGFR - 2 composition as CSF1R and, inhibitors and application. thereof in particular, and provides a compound VEGFR - 2 with potent inhibition CSF1R and (and a pharmaceutical composition (1) containing the compound as shown) or an isomer, solvate, hydrate, of the compound in preparation of a medicament, of the compound or a pharmaceutical composition containing the compound. A compound or a pharmaceutical composition containing the compound in a pharmaceutically acceptable salt, comprises . g of a compound or, a pharmaceutical composition containing the. above compound in a pharmaceutically acceptable form. (by machine translation)

A practical synthesis of the PDE4 inhibitor, KW-4490

A practical and scalable synthesis of a PDE4 inhibitor KW-4490 (1) was developed. This improved synthesis features the construction of the 1-arylcyclohexene (9) by the Diels-Alder reaction followed by a newly established Brnsted acid-promoted hydrocyanation. Subsequent crystallization-induced dynamic resolution enabled the high-yield production of the desired cis-isomer (cis-8). The synthesis was achieved in seven steps in 37% overall yield.

DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE

An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, —(CH2)n—E1—CO—G1 (wherein E1 represents a bond, O, or NH; and G1 represents hydrogen, substituted or unsubstituted lower alkyl, OR6, or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents —C(R9)(R10)— or O; B represents O, NR11, —C(R12)(R13)—, or —C(R14)(R15)—C(R16)(R17)—; D represents (i) —C(R18)(R19)—X— (wherein X represents —C(R21)(R22)—, S, or NR23), (ii) —C(R19a)═Y— [Y represents —C(R24)—Z— (wherein Z represents CONH, CONHCH2, or a bond), or N], or (iii) a bond; and R5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.